Kyverna Therapeutics has submitted an investigational new drug (IND) application asking regulators for permission to begin clinical testing on…
Articles by Marisa Wexler, MS
The first participant has been dosed in a pivotal Phase 2/3 trial testing Biogen’s anti-inflammatory medication litifilimab (BIIB059) in…
Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE)…
The European Commission has approved Lupkynis (voclosporin) to treat active lupus nephritis, a serious complication of systemic lupus erythematosus (SLE)…
DxTerity Diagnostics’ interferon-1 gene signature test, which can be used to help guide treatment decisions for people with systemic…
Active lupus nephritis — kidney inflammation as a result of lupus — is associated with a much higher risk…
The Lupus Foundation of America and Lupus Canada are funding a new study to better understand the role…
The Lupus Research Alliance (LRA) has announced $9 million in grants — three awards each totaling $3 million — to…
Alpine Immune Sciences and Evotec announced the expansion of an agreement to manufacture ALPN-303, an experimental anti-inflammatory therapy…
The U.S. Food and Drug Administration (FDA) has extended the use of Benlysta (belimumab), given on top of standard therapy,…